Cancers, Vol. 11, Pages 690: Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer

Cancers, Vol. 11, Pages 690: Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer Cancers doi: 10.3390/cancers11050690 Authors: Arik Bernard Schulze Georg Evers Andrea Kerkhoff Michael Mohr Christoph Schliemann Wolfgang E. Berdel Lars Henning Schmidt Lung cancer is the leading cause of cancer-related deaths worldwide. With a focus on histology, there are two major subtypes: Non-small cell lung cancer (NSCLC) (the more frequent subtype), and small cell lung cancer (SCLC) (the more aggressive one). Even though SCLC, in general, is a chemosensitive malignancy, relapses following induction therapy are frequent. The standard of care treatment of SCLC consists of platinum-based chemotherapy in combination with etoposide that is subsequently enhanced by PD-L1-inhibiting atezolizumab in the extensive-stage disease, as the addition of immune-checkpoint inhibition yielded improved overall survival. Although there are promising molecular pathways with potential therapeutic impacts, targeted therapies are still not an integral part of routine treatment. Against this background, we evaluated current literature for potential new molecular candidates such as surface markers (e.g., DLL3, TROP-2 or CD56), apoptotic factors (e.g., BCL-2, BET), genetic alterations (e.g., CREBBP, NOTCH or PTEN) or vascular markers (e.g., VEGF, FGFR1 or CD13). Apart from these factors, the application of so-called ‘poly-(ADP)-ribose polymerases’ (PARP) inh...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) are aggressive neuroendocrine tumors with poor survival rates [1 –3]. For stage IV SCLC, treatment has not advanced significantly over the last decades and consists of palliative chemotherapy. The same applies to stage IV LCNEC, were no standard treatment exists and palliative chemotherapy with SCLC and non-small cell lung cancer (NSCLC) regimens are both deeme d appropriate [4]. Recently, targeted therapy focusing on delta like protein 3 (DLL3) has received attention to improve outcomes for SCLC and LCNEC [5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Purpose of review The current article reviews the state of art of prevention strategies for brain metastases from solid tumors and touches both old pivotal studies and new directions of personalized molecular approaches. Recent findings Prophylactic cranial irradiation (PCI) has a definite role in the prevention of relapse into the brain for patients with small cell lung cancer (SCLC) responding to chemotherapy and radiotherapy as it prolongs overall survival (OS). However, the risk of late cognitive deficit following whole brain radiotherapy (WBRT) in this patient population is still not well known. Conversely, PCI s...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: BRAIN AND NERVOUS SYSTEM: Edited by Marc Sanson Source Type: research
Conclusions: Total FAK and activated FAK expressions are significantly higher in lung cancer than in normal lung, and significantly higher in SCLC compared to NSCLC, but are not prognostic biomarkers in this study.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Lung cancer remains the most common cause of cancer mortality, with approximately 1.81 million patients diagnosed with the disease in 2012 [1]. The two main categories of lung cancer are non –small-cell lung cancer (NSCLC), which includes 80% of all lung cancers, and small-cell lung cancer (SCLC), which accounts for the remaining 20% [2]. Radical surgery remains a treatment mainstay for early-stage NSCLC; however, many patients with NSCLC are not candidates for surgery due to comorbid ities, such as cardiopulmonary dysfunction, stage I, II or chronic obstructive pulmonary disease or tumour size during stages III and ...
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
Authors: Polański J, Jankowska-Polańska B, Mazur G, Chabowski M Abstract Behavioral cognitive therapy is recommended for lung cancer-related pain. The aim of the study was to analyze the strategies of coping with pain in relation to the histological type of lung cancer. The study included 257 lung cancer patients, divided into small cell lung carcinoma (SCLC) group (n = 72) and non-small cell lung carcinoma (NSCLC) group (n = 185). Pain was evaluated on a visual analog scale (VAS), while pain-coping strategies with the Coping Strategies Questionnaire. The two groups differed concerning the per...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Conclusion Gefitinib, erlotinib, and afatinib have similar effectiveness in advanced stage N SCLC with EGFR mutation positive. Afatinib tends to be associated with longer PFS but further investigation is required. DOI: 10.3779/j.issn.1009-3419.2019.09.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSION: Minority patients with lung cancer have significantly higher end-of-life medical expenditures than NH white patients, which may be explained by a greater intensity of care in the end-of-life period. IMPLICATIONS FOR PRACTICE: This study investigated racial-ethnic disparities in the cost and utilization of medical care among lung cancer patients during the end-of-life period. Compared with non-Hispanic white patients, racial-ethnic minority patients were more likely to receive intensive care in their final month of life and had statistically significantly higher end-of-life care costs. The findings of this ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Worldwide, lung cancer is the most common malignant tumor, accounting for 1.69 million new cases in 2015 [1], and remains the leading cause of cancer-related mortality with a predicted 5-year survival rate of 8 –13% [2]. Histopathologically, lung cancer is broadly categorized as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) with the latter constituting approximately 85% of the cases [3]. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) with demonstrated high sensitivit y and specificity for tumor detection has become the standard of care in baseline staging and restaging for both S...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Lung cancer is the leading cause of cancer-related deaths worldwide and can be broadly classified into two types: non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). The former represents 85% of all lung cancer [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
enkins Lung cancer is the leading cause of cancer-related mortality, which histologically is classified into small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancer diagnoses, with the majority of patients presenting with lung adenocarcinoma (LAC). KRAS mutations are a major driver of LAC, and are closely related to cigarette smoking, unlike mutations in the epidermal growth factor receptor (EGFR) which arise in never-smokers. Although the past two decades have seen fundamental progress in the treatment and diagnosis of NSCLC, NSCLC still is predomin...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroschisis Repair | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Small Cell Lung Cancer